Zuanette Ramos-Robles
Cardiovascular Disease · San Juan, PRNPI 1487071783
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,651 of the $12,558 with a category attached, or 68.9%. 18 manufacturers reported payments, led by Abbott at 31.6% of the total. Reporting peaked in 2020 at $5,080 and has fallen 81.9% since, to $919 in 2025.
Across 213 payments — averaging $58.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$2K
- Johnson & Johnson$2K
- Boehringer Ingelheim$1K
- PBG Puerto Rico LLC$879
- AstraZeneca$517
- plus $2K from 12 others
What the payments were for
- Consulting fees$1,35011%
- Travel & lodging$2,42919%
- Food & beverage$8,65169%
- Education$1271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $3,969 |
| Medtronic(2 entities) | 26 | $2,332 |
| Johnson & Johnson | 15 | $1,775 |
| Boehringer Ingelheim | 25 | $1,161 |
| PBG Puerto Rico LLC | 44 | $879 |
| AstraZeneca | 16 | $517 |
| Amgen | 4 | $382 |
| Boston Scientific | 8 | $365 |
| E.r. Squibb & Sons, L.L.C. | 9 | $312 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $256 |
| Bayer | 2 | $246 |
| Pfizer Pharmaceuticals LLC | 1 | $121 |
| Novartis | 3 | $69 |
| Bayer Puerto Rico Inc. | 3 | $61 |
| CSL Behring | 1 | $49 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Merck | 1 | $21 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$2,068
- XARELTO$1,350
- Micra$730
- JARDIANCE$713
- EP-WorkMate Recording System$513
- Repatha$362
- ENSITE$264
- FARXIGA$250
- ELIQUIS$240
- Amplia MRI$163
- Cobalt$157
- Azure$134
- Kerendia$121
- CoreValve Evolut$118
- VISA AF MRI VR SURESCAN$118
- Allure CRT Pacemaker$114
- Resolute$109
- Multi-Link Vision coronary stent system$106
- Claria MRI$102
- Reveal LINQ$102
How this compares
$12,558 in reported general payments places this provider in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 166 | $118,621 |
| JardianceEmpagliflozin | 84 | $54,324 |
| XareltoRivaroxaban | 63 | $41,893 |
| Repatha SureclickEvolocumab | 33 | $18,555 |
| FarxigaDapagliflozin Propanediol | 26 | $16,330 |
| Atorvastatin Calcium | 1,088 | $8,531 |
| Metoprolol Succinate | 402 | $4,847 |
| Rosuvastatin Calcium | 392 | $4,693 |
| Losartan Potassium | 560 | $4,581 |
| Chlorthalidone | 392 | $4,479 |
| Irbesartan | 161 | $2,865 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 25 | $2,851 |
| Candesartan Cilexetil | 39 | $2,678 |
| Nifedipine ErNifedipine | 119 | $2,397 |
| Amlodipine Besylate | 414 | $2,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $118,621166 claims |
| Boehringer IngelheimJardiance | $1,161 | $54,32484 claims |
| Johnson & JohnsonXarelto | $1,775 | $41,89363 claims |
| AstraZenecaFarxiga | $517 | $16,33026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in San Juan
- Manuel GuzmanSan Juan$203K
- Ramon PereaSan Juan$68K
- Francisco Merced-OrtizSan Juan$54K
- Sonia VicentySan Juan$23K
- Sonia Velazquez-NavarroSan Juan$17K
- Pedro Vargas-OteroSan Juan$15K
- Ricardo ColacioppoSan Juan$14K
- Jose Kareh CorderoSan Juan$13K
- William Borges CancelSan Juan$13K
- Edwin Rodriguez CruzSan Juan$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.